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vhis issue continues the format of a point/counter point
discussion of controversial and technically challenging
reas in cardiothoracic surgery involving adult cardiac, pedi-
tric cardiac, and general thoracic topics. In this issue, we
ave three complex and controversial situations in each of
he specialties. The issue of ischemic mitral regurgitation is
ne that continues to defy surgeons and cardiologists in deal-
ng with moderate to moderately severe mitral regurgitation
espite new approaches and new annuloplasty rings. Proce-
ures for treating hypoplastic left heart are still undergoing
volution and modification. Finally, in the staging and treat-
ent of lung cancer, a debate still exists in today’s general
horacic circles regarding the initial approach to this disease.
As always I am indebted to our Associate Editors, Drs.
undt, Jonas, and Mentzer for organizing a superb issue of
ontroversial technical problems.
perative Repair of
schemic Mitral Regurgitation
he grave prognostic consequences of mitral regurgitation
econdary to ischemic coronary artery disease are now appar-
nt. Surgeons have long recognized the increased operative
isk of such patients; we are now increasingly aware of their
ismal late survival as well. As experience with the surgical
reatment of end-stage heart disease has grown, so too has
nterest in attacking the problem of ischemic mitral regurgi-
ation head-on. Dr. Patrick McCarthy has had a longstanding
nterest in ischemic mitral regurgitation and, in particular, its
orrection using ring annuloplasty. In this issue, he and his
olleague at Northwestern University, Dr. EdwinMcGee, dis-
uss the repair of ischemic mitral regurgitation both by an-
uloplasty alone, and by mitral replacement. As a counter-
oint, Drs. Irving Kron and Benjamin Peeler present a more
ggressive approach to addressing the accompanying—or
erhaps causal—ventricular geometric abnormality present
n this condition. Unhappy with the rate of late recurrence of
itral regurgitation for ischemic disease, these authors have
dded a subvalvular suture to effect posterior papillary mus-
le relocation in addition to annuloplasty.
The ultimate place of mitral repair in the treatment of
schemic mitral regurgitation remains controversial. To the
urprise of many the operative mortality reported for mitral
epair in this setting in recent years has proven low. The
elative increase in risk over coronary bypass alone is a matter a
522-2942/05/$-see front matter © 2005 Elsevier Inc. All rights reserved.
oi:10.1053/j.optechstcvs.2005.06.004f controversy. Unfortunately, the actual effectiveness of re-
air in improving late survival remains unproven as well.
one the less, the cardiac surgeon todaymust be equipped to
eal with this entity.
orwood Procedure:
lalock versus Sano Shunt
he congenital cardiac controversy that is the focus of this
ssue is currently a hot topic. Many centers are firmly of the
pinion that the right ventricle to pulmonary artery shunt
opularized by Sano for the stage 1 Norwood procedure has
een a remarkably important development. On the other
and, several centers with large experience with the Nor-
ood procedure and low mortality rates for several years are
ess convinced that the Blalock shunt should be abandoned.
im Tweddell from the Milwaukee Children’s Hospital has
llustrated his approach to the Norwood procedure incorpo-
ating a modified Blalock shunt while Shunji Sano from
kayama Japan has illustrated his technique for constructing
he shunt that bears his name.
ymph Nodes and Lung Cancer
he controversy in this issue of Operative Techniques in
ardiothoracic Surgery focuses on lymph nodes and lung can-
er. The article “Mediastinal Staging Prior to Surgical Resec-
ion” describes the technical approach to mediastinoscopy
nd thoracoscopic staging. Drs. Maskovitz and Rusch de-
cribe their approach to lymphadenectomy in the article “Re-
ection and Mediastinal Lymph Node Dissection.”
“Mediastinal Staging Prior to Surgical Resection” argues
hat mediastinoscopy offers a safe and effective means of
btaining histologic evidence of tumor stage prior to defini-
ive surgical resection. The role of pre-therapy staging is
ikely to evolve in the future; nonetheless, the ability of the
horacic surgeon to obtain pre-treatment histologic staging
ith a minimally morbid outpatient procedure is an advan-
age envied in many areas of surgical oncology. From the
iewpoint of the individual patient, the histologic findings
ay suggest the necessity of additional radiographic staging
r the utility of neoadjuvant therapy. The importance of pre-
reatment histologic analysis will likely increase with the de-
elopment of predictive biomarkers and targeted chemother-
py. From the viewpoint of clinical trials, pre-resectional
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Drs. Maskovitz and Rusch describe an approach that is
ften positioned as an alternative to mediastinoscopy; how-
ver, mediastinal lymph node dissection may also comple-
ent invasive mediastinal staging. When invasive mediasti-
al staging is performed prior to neoadjuvant chemotherapy,
ymph node dissection at the time of definitive surgery allowsor the evaluation of the treatment response like comparing
issue both before and after therapy. The ability to perform
erial analyses of metastatic cancer from the same patient is a
nique aspect of lung cancer therapy. It is in advantage that
eeds to be exploited in future clinical trials.
Lawrence H. Cohn, MD
Editor
